Akan Biosciences
1 known investors
AKAN Biosciences is a biotechnology and cellular therapy company developing injectable, adipose stem cell-based regenerative products to treat degenerative diseases and injuries. Its lead product, StroMel, is in Phase 2 clinical trials for knee osteoarthritis, with additional trials planned for other joints, wound healing, Crohn's disease, sports injuries, and autism.
BiotechHealthtechMedical Devices
Investors · 1
Competitors · 9
by search overlapIQVIA6 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Akebia Therapeutics4 shared keywordsAkebia Therapeutics develops FDA-approved drug therapies for the treatment of kidney disease. The company is a fully integrated biopharmaceutical organization with a nephrology-focused commercial team and development capabilities.
AskBio4 shared keywordsAskBio develops gene therapies based on adeno-associated virus (AAV) technology, with a clinical pipeline targeting central nervous system, neuromuscular, metabolic, and cardiovascular disorders. Founded in 2001 and operating as a subsidiary of Bayer AG, the company runs research and in-house AAV manufacturing across the US and Europe.
Archon4 shared keywordsArchon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Ark Biosciences3 shared keywordsArk Biosciences (爱科百发) is a biopharmaceutical company developing innovative drugs for respiratory diseases and pediatric conditions, with a pipeline covering RSV, ADHD, idiopathic pulmonary fibrosis (IPF), and COPD. Its products include the RSV fusion inhibitor ziresovir (AK0529) and an approved ADHD treatment, aimed at patients in China and globally.
Doximity3 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Aro Biotherapeutics3 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Kenaitx3 shared keywordsKenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for neurological conditions such as Parkinson's disease. Its lead program, RNDP-001, is being evaluated in the REPLACE Phase 1b/2a clinical trial for idiopathic Parkinson's disease.
Companies competing with Akan Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Akan Biosciences do?
- AKAN Biosciences is a biotechnology and cellular therapy company developing injectable, adipose stem cell-based regenerative products to treat degenerative diseases and injuries. Its lead product, StroMel, is in Phase 2 clinical trials for knee osteoarthritis, with additional trials planned for other joints, wound healing, Crohn's disease, sports injuries, and autism.
- Who are Akan Biosciences's investors?
- Akan Biosciences's investors include 2Flo Ventures.